Amyloid-β

BSBM6 is an amyloid-β (Aβ) inhibitor that effectively prevents Aβ aggregation and modulates its formation. This compound has been shown to reduce soluble oligomers, thereby potentially aiding in the treatment of neurodegenerative diseases associated with amyloid pathology. BSBM6 serves as a valuable tool for researchers studying Aβ dynamics and for the design of novel aggregation-modulating ligands.

β Amyloid (1-42) (scrambled) serves as a negative control for β-Amyloid (1-42), a peptide associated with Alzheimer's disease progression. The scrambled sequence ensures that any observed biological effects in experimental settings can be attributed specifically to the active form of β-Amyloid (1-42). This reagent is useful for validating experimental results in studies focused on amyloid pathology and neurodegenerative research.

CHF5022 is an inhibitor of Aβ42 secretion, exhibiting an IC50 value of 92 μM. In addition to its primary activity, CHF5022 demonstrates modest inhibition of Aβ40 at non-cytotoxic concentrations, achieving a reduction of approximately 22.2% at 100 μM. This compound is valuable for research into Alzheimer's disease and the mechanisms of amyloid-beta peptide regulation.

Kayaflavone is a biflavonoid of the amentoflavone type known for its inhibitory activity against amyloid-β42 cytotoxicity in PC-12 cells, exhibiting an EC50 value of 5.29 μM. This compound holds potential for research applications in Alzheimer’s disease, contributing to the understanding of amyloid-related neurotoxicity and its implications in neurodegenerative processes.

β-Amyloid (1-8) is an Aβ fragment that functions as a crucial component in the study of Alzheimer's disease. This peptide is instrumental in investigating the aggregation and toxicity of amyloid-beta, which are key features of neurodegeneration. It serves as a valuable tool for researchers exploring potential therapeutic strategies and the underlying mechanisms of amyloid pathology.

Aβ aggregation modulator-1 is a stimulator of amyloid-β (Aβ) fibrillogenesis, targeting the stabilization of β-sheet-rich protofibrils and fibrils by binding to hydrophobic residues in Aβ peptides. This compound accelerates Aβ polymerization while decreasing the concentration of small, toxic Aβ oligomers in heterogeneous aggregation reactions. Additionally, Aβ aggregation modulator-1 mitigates the inhibition of long-term potentiation (LTP) caused by Aβ oligomers in hippocampal brain slices. This reagent is valuable for researching Alzheimer's disease (AD) and its underlying mechanisms.

Azeliragon dihydrochloride is a selective inhibitor of the receptor for advanced glycation end products (RAGE). This compound demonstrates the ability to cross the blood-brain barrier and has been investigated for its potential to mitigate disease progression in patients with mild Alzheimer's disease. Its mechanism of action involves reducing neuroinflammation and promoting neuronal health, making it a promising candidate for research focused on Alzheimer's disease therapeutics.

APP Modulator-1 is a compound that specifically targets the amyloid precursor protein (APP) to influence its processing and thereby modulate the production of amyloid-beta peptides. This activity suggests potential applications in Alzheimer's disease research, particularly in understanding the mechanisms of amyloid plaque formation. APP Modulator-1 is suitable for studies aimed at elucidating the role of APP in neurodegenerative disorders and developing therapeutic strategies for related conditions.

Dihydroergocristine mesylate is a potent inhibitor of γ-secretase, targeting the enzyme responsible for the generation of amyloid-β peptides implicated in Alzheimer’s disease. It effectively reduces the production of these peptides by binding directly to γ-secretase and Nicastrin, exhibiting equilibrium dissociation constants (Kd) of 25.7 nM and 9.8 μM, respectively. This compound can be utilized in research aimed at unraveling the mechanisms of Alzheimer’s pathology and developing potential therapeutic strategies.